ArticleFrontiers in immunology2019
A DNA Vaccine Encoding the Gn Ectodomain of Rift Valley Fever Virus Protects Mice via a Humoral Response Decreased by DEC205 Targeting.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- The 40Fp8 vaccine strain is safe and protects pregnant ewes from a virulent RVFV challenge.NPJ vaccines · 2025Article
- Harnessing cytokines: innovative adjuvants for improved veterinary vaccine efficacy.Frontiers in immunology · 2025Review
- The Adaptive Immune Response againstViruses · 2024Review
- Guidelines for In Vitro Production and Quantification of Rift Valley Fever Virus.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.NPJ vaccines · 2023Review
- Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine.Frontiers in immunology · 2023Review
- Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses.Frontiers in cellular and infection microbiology · 2023Review
- Intranasal Exposure to Rift Valley Fever Virus Live-Attenuated Strains Leads to High Mortality Rate in Immunocompetent Mice.Viruses · 2022Article
- Seroprevalence of brucellosis, Q fever and Rift Valley fever in domestic ruminants in Guinea in 2017-2019.BMC veterinary research · 2022Article
- Article
- Simultaneous Infection With Porcine Reproductive and Respiratory Syndrome and Influenza Viruses Abrogates Clinical Protection Induced by Live Attenuated Porcine Reproductive and Respiratory Syndrome Vaccination.Frontiers in immunology · 2021Article
- Rift Valley Fever - epidemiological update and risk of introduction into Europe.EFSA journal. European Food Safety Authority · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Rift Valley fever virus (RVFV) is responsible for a serious mosquito-borne viral disease in humans and ruminants. The development of a new and safer vaccine is urgently needed due to the risk of introduction of this arbovirus into RVFV-free continents. We recently showed that a DNA vaccine encoding eGn, the ectodomain of the RVFV Gn glycoprotein, conferred a substantial protection in the sheep natural host and that the anti-eGn IgG levels correlated to protection. Addressing eGn to DEC205 reduced the protective efficacy while decreasing the antibody and increasing the IFNγ T cell responses in sheep. In order to get further insight into the involved mechanisms, we evaluated our eGn-encoding DNA vaccine strategy in the reference mouse species. A DNA vaccine encoding eGn induced full clinical protection in mice and the passive transfer of immune serum was protective. This further supports that antibodies, although non-neutralizing
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.